Tonix Pharmaceuticals stock halted ahead of FDA approval news
Materion Corporation (NYSE:MTRN) reported that on Friday, its Compensation and Human Capital Committee approved a special grant of 4,696 service-based, share-settled restricted stock units (RSUs) to Shelly Chadwick, the company’s Vice President, Finance and Chief Financial Officer. The announcement was made in a statement filed with the Securities and Exchange Commission.
The RSUs were granted under the Materion Corporation 2025 Equity and Incentive Compensation Plan and are subject to the terms of the applicable RSU award agreement. According to the filing, the RSUs and any related dividend equivalents are scheduled to vest in full and pay out in company shares on the third anniversary of the grant date, provided that Ms. Chadwick remains employed through the vesting date.
The agreement also outlines alternative vesting conditions. The RSUs may vest earlier in the event of certain circumstances, including retirement, death, disability, certain involuntary terminations without cause, or a “double-trigger” change in control, as detailed in the award agreement.
Materion Corporation is based in Mayfield Heights, Ohio, and its common stock is listed on the New York Stock Exchange under the ticker MTRN. This information is based on a press release statement contained in the company’s recent SEC filing.
In other recent news, Materion Corporation reported its second-quarter earnings for 2025, exceeding Wall Street expectations. The company achieved an earnings per share (EPS) of $1.37, surpassing the anticipated $1.16. Revenue also outperformed forecasts, reaching $431.7 million compared to the expected $406.35 million. Additionally, Materion announced a quarterly dividend of $0.14 per share, payable on September 5, 2025, to shareholders of record as of August 22, 2025. These developments reflect positively on the company’s financial performance. Furthermore, the company’s stock showed a favorable response in pre-market trading.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.